Summary of Study ST001232

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000825. The data can be accessed directly via it's Project DOI: 10.21228/M81X1W This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001232
Study TitleCombining stage - specificity and metabolomic profiling to advance drug discovery for malaria
Study TypeDrug Exposure
Study SummaryMetabolic examination/confirmation of MoA stage-specificity observed in study
Pennsylvania State University
LaboratoryLlinĂ¡s Laboratory
Last NameOwen
First NameEdward
Address6014 Goldenrod Court
Submit Date2019-07-09
Analysis Type DetailLC-MS
Release Date2020-03-03
Release Version1
Edward Owen Edward Owen application/zip

Select appropriate tab below to view additional metadata details:


Treatment ID:TR001315
Treatment Summary:Infected Red Blood cells were exposed to Antimalarial Compounds, associated with sample names. No treatment (as in the case of blanks) denotes these samples did not undergo the treatment incubation (blanks are made at the point of extraction in this case), whereas treated with no drug relates that these samples (no drug or ND) underwent the same treatment incubation as other treated samples, but in this case as a negative control with no drug administered.
Treatment Compound:Atovaquone, Dihydroartemisinin (DHA), Ferroquin (FQ), GNF-Pf-5660, KAI407, Lumefantrine (LMF), Methylene Blue, MMV00017 (Naphthoquine), MMV000442, MMV00787, MMV007181, MMV019555, MMV020746, MMV021735, MMV022224, MMV022478, MMV027496, MMV030666, MMV085071, MMV665794, MMV665939, MMV667491, MMV668311, MMV675939, Mefloquine (MQ), Piperaquine (PPQ), WLL
Treatment Route:Addition to media
Treatment Dose:10xIC50
Treatment Dosevolume:Always less than 10 uL per 5 mL sample
Treatment Doseduration:2.5 hours
Treatment Vehicle:Stocks kept in either DMSO or Water
Cell Storage:Temperature/Gas Mixture controlled incubator
Cell Growth Container:6-well plate
Cell Growth Config:5 mL per well, each with 1x10^8 cells
Cell Media:RPMI 1640 w/ Albumax, Gentamycin, Hypoxanthine, HEPES, Sodium Bicarbonate
Cell Harvesting:PBS Wash followed by 90% methanol extraction